Loading...

APC anti-human CD4 Antibody APC anti-human CD4 Antibody

Pricing & Availability
Clone
RPA-T4 (See other available formats)
Regulatory Status
RUO
Workshop
IV T114
Other Names
T4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
300537 500 tests SEK2403
Check Availability


Need larger quantities of this item?
Request Bulk Quote
300514 100 tests SEK605
Check Availability


Need larger quantities of this item?
Request Bulk Quote
300552 100 µg SEK656
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules, and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

The RPA-T4 antibody binds to the D1 domain of CD4 (CDR1 and CDR3 epitopes) and can block HIV gp120 binding and inhibit syncytia formation. Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen sections3,4,5, blocking of T cell activation1,2, and spatial biology (IBEX)10,11.  This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300569 - 300574).

Application References
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. (Activ)
  2. Moir S, et al. 1999. J. Virol. 73:7972. (Activ)
  3. Deng MC, et al. 1995. Circulation 91:1647. (IHC)
  4. Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC)
  5. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  6. Lan RY, et al. 2006. Hepatology 43:729.
  7. Zenaro E, et al. 2009. J. Leukoc. Biol. 86:1393. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Tang M, et al. 2019. Biomed Res Int. 2019:1050285. PubMed
  2. Penkava F, et al. 2020. Nat Commun. 3.76875. PubMed
  3. Lehmkuhl P, et al. 2021. Cell Mol Immunol. 18:1677. PubMed
  4. Yuan H, et al. 2022. J Clin Exp Hematop. 62:52. PubMed
  5. Hong Y, et al. 2022. J Leukoc Biol. 112:425. PubMed
  6. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  7. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  8. Ogura H, et al. 2022. Nat Commun. 13:7063. PubMed
  9. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  10. Donadei C, et al. 2023. J Clin Med. 12:. PubMed
  11. Nakano Y, et al. 2017. PLoS Pathog. 13:e1006348. PubMed
  12. Carpenter RS, et al. 2019. Sci Rep. 9:19105. PubMed
  13. Wang F, et al. 2018. Oncogenesis. 7:41. PubMed
  14. Eleftheriadis T, et al. 2021. Int J Mol Sci. 22:. PubMed
  15. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  16. Koelsch K, et al. 2013. PLoS One. 8:50068. PubMed
  17. Tang-Huau TL, et al. 2018. Nat Commun. 9:2570. PubMed
  18. Eri Yamada et al. 2018. Cell host & microbe. 23(1):110-120 . PubMed
  19. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  20. Fletcher H, et al. 2016. Nat Commun. 7: 11290. PubMed
  21. Park JA, et al. 2021. J Hematol Oncol. 14:142. PubMed
  22. Gludish DW, et al. 2020. Sci Rep. 10:19900. PubMed
  23. Stuart T, et al. 2019. Cell. 177:1888. PubMed
  24. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
  25. Kim ST, et al. 2022. Nat Commun. 13:1970. PubMed
  26. Kerstein A, et al. 2016. J Autoimmun. S0896-8411(16)30186-X. PubMed
  27. Vyborova A, et al. 2022. Front Immunol. 13:915366. PubMed
  28. Ng CY, et al. 2022. EMBO Rep. 23:e54271. PubMed
  29. Jancewicz I, et al. 2021. Cancers (Basel). 13:. PubMed
  30. Martín Monreal MT, et al. 2021. Front Immunol. 12:716250. PubMed
  31. Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed
  32. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  33. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
  34. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  35. André M, et al. 2010. J Immunol. 185:2710. PubMed
  36. Reichwald K, et al. 2014. PLoS One. 9:105627. PubMed
  37. Usero L, et al. 2016. Diabetes. 65: 2356 - 2366. PubMed
  38. Park MJ, et al. 2019. J Immunol. 203:127. PubMed
  39. Kim D, et al. 2020. Nat Med. 26:236. PubMed
  40. Zuccato C, et al. 2022. Ther Adv Hematol. 13:20406207221100648. PubMed
  41. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  42. Huber JE, et al. 2020. J Immunol. 204:1101. PubMed
  43. Lundy SK, et al. 2018. Front Med (Lausanne). 0.38125. PubMed
  44. O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed
  45. Iwata A, et al. 2017. Nat Immunol. 18:563. PubMed
  46. Lotfi S, et al. 2020. Retrovirology. 17:20. PubMed
  47. Ng CY, et al. 2022. EMBO Rep. 23:e55871. PubMed
  48. Cui J, et al. 2019. Neuro Oncol. 21:1436. PubMed
  49. Beyer AI, et al. 2017. Stem Cells Dev. 26:102. PubMed
  50. Huang LJ, et al. 2021. Immunity. 54(8):1728-1744.e7. PubMed
  51. Dyson MR, et al. 2020. MAbs. 12:1829335. PubMed
  52. Koh WH, et al. 2020. STAR Protoc. 1:100203. PubMed
  53. Martin GE, et al. 2018. Front Immunol. 1.019444444. PubMed
  54. Ma S, et al. 2022. Nat Commun. 13:4118. PubMed
  55. Li B, et al. 2019. Oncogenesis. 8:17. PubMed
  56. Chang XL, et al. 2021. Nat Commun. 12:3343. PubMed
  57. Pawlicki JM, et al. 2021. Cancer Res. 81:3241. PubMed
  58. Olety B, et al. 2021. Sci Adv. 7:eabj7398. PubMed
  59. Tang M, et al. 2019. Biomed Res Int. 2019:1050285. PubMed
  60. Penkava F, et al. 2020. Nat Commun. 3.76875. PubMed
  61. Lehmkuhl P, et al. 2021. Cell Mol Immunol. 18:1677. PubMed
  62. Yuan H, et al. 2022. J Clin Exp Hematop. 62:52. PubMed
  63. Hong Y, et al. 2022. J Leukoc Biol. 112:425. PubMed
  64. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  65. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  66. Ogura H, et al. 2022. Nat Commun. 13:7063. PubMed
  67. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  68. Donadei C, et al. 2023. J Clin Med. 12:. PubMed
  69. Nakano Y, et al. 2017. PLoS Pathog. 13:e1006348. PubMed
  70. Carpenter RS, et al. 2019. Sci Rep. 9:19105. PubMed
  71. Wang F, et al. 2018. Oncogenesis. 7:41. PubMed
  72. Eleftheriadis T, et al. 2021. Int J Mol Sci. 22:. PubMed
  73. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  74. Koelsch K, et al. 2013. PLoS One. 8:50068. PubMed
  75. Tang-Huau TL, et al. 2018. Nat Commun. 9:2570. PubMed
  76. Eri Yamada et al. 2018. Cell host & microbe. 23(1):110-120 . PubMed
  77. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  78. Fletcher H, et al. 2016. Nat Commun. 7: 11290. PubMed
  79. Park JA, et al. 2021. J Hematol Oncol. 14:142. PubMed
  80. Gludish DW, et al. 2020. Sci Rep. 10:19900. PubMed
  81. Stuart T, et al. 2019. Cell. 177:1888. PubMed
  82. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
  83. Kim ST, et al. 2022. Nat Commun. 13:1970. PubMed
  84. Kerstein A, et al. 2016. J Autoimmun. S0896-8411(16)30186-X. PubMed
  85. Vyborova A, et al. 2022. Front Immunol. 13:915366. PubMed
  86. Ng CY, et al. 2022. EMBO Rep. 23:e54271. PubMed
  87. Jancewicz I, et al. 2021. Cancers (Basel). 13:. PubMed
  88. Martín Monreal MT, et al. 2021. Front Immunol. 12:716250. PubMed
  89. Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed
  90. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  91. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
  92. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  93. André M, et al. 2010. J Immunol. 185:2710. PubMed
  94. Reichwald K, et al. 2014. PLoS One. 9:105627. PubMed
  95. Usero L, et al. 2016. Diabetes. 65: 2356 - 2366. PubMed
  96. Park MJ, et al. 2019. J Immunol. 203:127. PubMed
  97. Kim D, et al. 2020. Nat Med. 26:236. PubMed
  98. Zuccato C, et al. 2022. Ther Adv Hematol. 13:20406207221100648. PubMed
  99. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  100. Huber JE, et al. 2020. J Immunol. 204:1101. PubMed
  101. Lundy SK, et al. 2018. Front Med (Lausanne). 0.38125. PubMed
  102. O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed
  103. Iwata A, et al. 2017. Nat Immunol. 18:563. PubMed
  104. Lotfi S, et al. 2020. Retrovirology. 17:20. PubMed
  105. Ng CY, et al. 2022. EMBO Rep. 23:e55871. PubMed
  106. Cui J, et al. 2019. Neuro Oncol. 21:1436. PubMed
  107. Beyer AI, et al. 2017. Stem Cells Dev. 26:102. PubMed
  108. Huang LJ, et al. 2021. Immunity. 54(8):1728-1744.e7. PubMed
  109. Dyson MR, et al. 2020. MAbs. 12:1829335. PubMed
  110. Koh WH, et al. 2020. STAR Protoc. 1:100203. PubMed
  111. Martin GE, et al. 2018. Front Immunol. 1.019444444. PubMed
  112. Ma S, et al. 2022. Nat Commun. 13:4118. PubMed
  113. Li B, et al. 2019. Oncogenesis. 8:17. PubMed
  114. Chang XL, et al. 2021. Nat Commun. 12:3343. PubMed
  115. Pawlicki JM, et al. 2021. Cancer Res. 81:3241. PubMed
  116. Olety B, et al. 2021. Sci Adv. 7:eabj7398. PubMed
RRID
AB_2562051 (BioLegend Cat. No. 300537)
AB_314082 (BioLegend Cat. No. 300514)
AB_2564153 (BioLegend Cat. No. 300552)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Dendritic cells, Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC/Cyanine7 anti-human CD4 RPA-T4 FC
Brilliant Violet 785™ anti-human CD4 RPA-T4 FC
Brilliant Violet 605™ anti-human CD4 RPA-T4 FC
Brilliant Violet 711™ anti-human CD4 RPA-T4 FC
APC/Fire™ 750 anti-human CD4 RPA-T4 FC
CD4 Fluorophore Sampler Kit RPA-T4 FC
CD4 Fluorophore Sampler Kit with Veri-Cells™ PBMC RPA-T4 FC
TotalSeq™-A0072 anti-human CD4 RPA-T4 PG
TotalSeq™-B0072 anti-human CD4 RPA-T4 PG
TotalSeq™-C0072 anti-human CD4 RPA-T4 PG
Ultra-LEAF™ Purified anti-human CD4 RPA-T4 FC,CyTOF®,Activ,Block,IHC
APC anti-human CD4 RPA-T4 FC
Biotin anti-human CD4 RPA-T4 FC
FITC anti-human CD4 RPA-T4 FC,SB
PE anti-human CD4 RPA-T4 FC
PE/Cyanine5 anti-human CD4 RPA-T4 FC
PE/Cyanine7 anti-human CD4 RPA-T4 FC
Purified anti-human CD4 RPA-T4 FC,CyTOF®,Activ,Block,IHC
Alexa Fluor® 488 anti-human CD4 RPA-T4 FC,ICC
Alexa Fluor® 647 anti-human CD4 RPA-T4 FC,SB
Pacific Blue™ anti-human CD4 RPA-T4 FC
Brilliant Violet 421™ anti-human CD4 RPA-T4 FC,ICC
Alexa Fluor® 700 anti-human CD4 RPA-T4 FC,SB
PerCP anti-human CD4 RPA-T4 FC
PerCP/Cyanine5.5 anti-human CD4 RPA-T4 FC
Brilliant Violet 570™ anti-human CD4 RPA-T4 FC
Brilliant Violet 650™ anti-human CD4 RPA-T4 FC
Purified anti-human CD4 (Maxpar® Ready) RPA-T4 FC,CyTOF®
Alexa Fluor® 594 anti-human CD4 RPA-T4 FC,ICC
Brilliant Violet 510™ anti-human CD4 RPA-T4 FC
PE/Dazzle™ 594 anti-human CD4 RPA-T4 FC
TotalSeq™-D0072 anti-human CD4 RPA-T4 PG
APC/Fire™ 810 anti-human CD4 RPA-T4 FC
Spark UV™ 387 anti-human CD4 Antibody RPA-T4 FC
Go To Top Version: 3    Revision Date: 12-11-2023

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
RPA-T4 (See other available formats)
Regulatory Status
RUO
Workshop
IV T114
Other Names
T4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
300537 500 tests SEK2403
Check Availability


Need larger quantities of this item?
Request Bulk Quote
300514 100 tests SEK605
Check Availability


Need larger quantities of this item?
Request Bulk Quote
300552 100 µg SEK656
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules, and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

The RPA-T4 antibody binds to the D1 domain of CD4 (CDR1 and CDR3 epitopes) and can block HIV gp120 binding and inhibit syncytia formation. Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen sections3,4,5, blocking of T cell activation1,2, and spatial biology (IBEX)10,11.  This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300569 - 300574).

Application References
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. (Activ)
  2. Moir S, et al. 1999. J. Virol. 73:7972. (Activ)
  3. Deng MC, et al. 1995. Circulation 91:1647. (IHC)
  4. Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC)
  5. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  6. Lan RY, et al. 2006. Hepatology 43:729.
  7. Zenaro E, et al. 2009. J. Leukoc. Biol. 86:1393. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Tang M, et al. 2019. Biomed Res Int. 2019:1050285. PubMed
  2. Penkava F, et al. 2020. Nat Commun. 3.76875. PubMed
  3. Lehmkuhl P, et al. 2021. Cell Mol Immunol. 18:1677. PubMed
  4. Yuan H, et al. 2022. J Clin Exp Hematop. 62:52. PubMed
  5. Hong Y, et al. 2022. J Leukoc Biol. 112:425. PubMed
  6. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  7. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  8. Ogura H, et al. 2022. Nat Commun. 13:7063. PubMed
  9. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  10. Donadei C, et al. 2023. J Clin Med. 12:. PubMed
  11. Nakano Y, et al. 2017. PLoS Pathog. 13:e1006348. PubMed
  12. Carpenter RS, et al. 2019. Sci Rep. 9:19105. PubMed
  13. Wang F, et al. 2018. Oncogenesis. 7:41. PubMed
  14. Eleftheriadis T, et al. 2021. Int J Mol Sci. 22:. PubMed
  15. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  16. Koelsch K, et al. 2013. PLoS One. 8:50068. PubMed
  17. Tang-Huau TL, et al. 2018. Nat Commun. 9:2570. PubMed
  18. Eri Yamada et al. 2018. Cell host & microbe. 23(1):110-120 . PubMed
  19. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  20. Fletcher H, et al. 2016. Nat Commun. 7: 11290. PubMed
  21. Park JA, et al. 2021. J Hematol Oncol. 14:142. PubMed
  22. Gludish DW, et al. 2020. Sci Rep. 10:19900. PubMed
  23. Stuart T, et al. 2019. Cell. 177:1888. PubMed
  24. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
  25. Kim ST, et al. 2022. Nat Commun. 13:1970. PubMed
  26. Kerstein A, et al. 2016. J Autoimmun. S0896-8411(16)30186-X. PubMed
  27. Vyborova A, et al. 2022. Front Immunol. 13:915366. PubMed
  28. Ng CY, et al. 2022. EMBO Rep. 23:e54271. PubMed
  29. Jancewicz I, et al. 2021. Cancers (Basel). 13:. PubMed
  30. Martín Monreal MT, et al. 2021. Front Immunol. 12:716250. PubMed
  31. Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed
  32. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  33. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
  34. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  35. André M, et al. 2010. J Immunol. 185:2710. PubMed
  36. Reichwald K, et al. 2014. PLoS One. 9:105627. PubMed
  37. Usero L, et al. 2016. Diabetes. 65: 2356 - 2366. PubMed
  38. Park MJ, et al. 2019. J Immunol. 203:127. PubMed
  39. Kim D, et al. 2020. Nat Med. 26:236. PubMed
  40. Zuccato C, et al. 2022. Ther Adv Hematol. 13:20406207221100648. PubMed
  41. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  42. Huber JE, et al. 2020. J Immunol. 204:1101. PubMed
  43. Lundy SK, et al. 2018. Front Med (Lausanne). 0.38125. PubMed
  44. O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed
  45. Iwata A, et al. 2017. Nat Immunol. 18:563. PubMed
  46. Lotfi S, et al. 2020. Retrovirology. 17:20. PubMed
  47. Ng CY, et al. 2022. EMBO Rep. 23:e55871. PubMed
  48. Cui J, et al. 2019. Neuro Oncol. 21:1436. PubMed
  49. Beyer AI, et al. 2017. Stem Cells Dev. 26:102. PubMed
  50. Huang LJ, et al. 2021. Immunity. 54(8):1728-1744.e7. PubMed
  51. Dyson MR, et al. 2020. MAbs. 12:1829335. PubMed
  52. Koh WH, et al. 2020. STAR Protoc. 1:100203. PubMed
  53. Martin GE, et al. 2018. Front Immunol. 1.019444444. PubMed
  54. Ma S, et al. 2022. Nat Commun. 13:4118. PubMed
  55. Li B, et al. 2019. Oncogenesis. 8:17. PubMed
  56. Chang XL, et al. 2021. Nat Commun. 12:3343. PubMed
  57. Pawlicki JM, et al. 2021. Cancer Res. 81:3241. PubMed
  58. Olety B, et al. 2021. Sci Adv. 7:eabj7398. PubMed
  59. Tang M, et al. 2019. Biomed Res Int. 2019:1050285. PubMed
  60. Penkava F, et al. 2020. Nat Commun. 3.76875. PubMed
  61. Lehmkuhl P, et al. 2021. Cell Mol Immunol. 18:1677. PubMed
  62. Yuan H, et al. 2022. J Clin Exp Hematop. 62:52. PubMed
  63. Hong Y, et al. 2022. J Leukoc Biol. 112:425. PubMed
  64. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  65. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  66. Ogura H, et al. 2022. Nat Commun. 13:7063. PubMed
  67. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  68. Donadei C, et al. 2023. J Clin Med. 12:. PubMed
  69. Nakano Y, et al. 2017. PLoS Pathog. 13:e1006348. PubMed
  70. Carpenter RS, et al. 2019. Sci Rep. 9:19105. PubMed
  71. Wang F, et al. 2018. Oncogenesis. 7:41. PubMed
  72. Eleftheriadis T, et al. 2021. Int J Mol Sci. 22:. PubMed
  73. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  74. Koelsch K, et al. 2013. PLoS One. 8:50068. PubMed
  75. Tang-Huau TL, et al. 2018. Nat Commun. 9:2570. PubMed
  76. Eri Yamada et al. 2018. Cell host & microbe. 23(1):110-120 . PubMed
  77. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  78. Fletcher H, et al. 2016. Nat Commun. 7: 11290. PubMed
  79. Park JA, et al. 2021. J Hematol Oncol. 14:142. PubMed
  80. Gludish DW, et al. 2020. Sci Rep. 10:19900. PubMed
  81. Stuart T, et al. 2019. Cell. 177:1888. PubMed
  82. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
  83. Kim ST, et al. 2022. Nat Commun. 13:1970. PubMed
  84. Kerstein A, et al. 2016. J Autoimmun. S0896-8411(16)30186-X. PubMed
  85. Vyborova A, et al. 2022. Front Immunol. 13:915366. PubMed
  86. Ng CY, et al. 2022. EMBO Rep. 23:e54271. PubMed
  87. Jancewicz I, et al. 2021. Cancers (Basel). 13:. PubMed
  88. Martín Monreal MT, et al. 2021. Front Immunol. 12:716250. PubMed
  89. Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed
  90. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  91. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
  92. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  93. André M, et al. 2010. J Immunol. 185:2710. PubMed
  94. Reichwald K, et al. 2014. PLoS One. 9:105627. PubMed
  95. Usero L, et al. 2016. Diabetes. 65: 2356 - 2366. PubMed
  96. Park MJ, et al. 2019. J Immunol. 203:127. PubMed
  97. Kim D, et al. 2020. Nat Med. 26:236. PubMed
  98. Zuccato C, et al. 2022. Ther Adv Hematol. 13:20406207221100648. PubMed
  99. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  100. Huber JE, et al. 2020. J Immunol. 204:1101. PubMed
  101. Lundy SK, et al. 2018. Front Med (Lausanne). 0.38125. PubMed
  102. O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed
  103. Iwata A, et al. 2017. Nat Immunol. 18:563. PubMed
  104. Lotfi S, et al. 2020. Retrovirology. 17:20. PubMed
  105. Ng CY, et al. 2022. EMBO Rep. 23:e55871. PubMed
  106. Cui J, et al. 2019. Neuro Oncol. 21:1436. PubMed
  107. Beyer AI, et al. 2017. Stem Cells Dev. 26:102. PubMed
  108. Huang LJ, et al. 2021. Immunity. 54(8):1728-1744.e7. PubMed
  109. Dyson MR, et al. 2020. MAbs. 12:1829335. PubMed
  110. Koh WH, et al. 2020. STAR Protoc. 1:100203. PubMed
  111. Martin GE, et al. 2018. Front Immunol. 1.019444444. PubMed
  112. Ma S, et al. 2022. Nat Commun. 13:4118. PubMed
  113. Li B, et al. 2019. Oncogenesis. 8:17. PubMed
  114. Chang XL, et al. 2021. Nat Commun. 12:3343. PubMed
  115. Pawlicki JM, et al. 2021. Cancer Res. 81:3241. PubMed
  116. Olety B, et al. 2021. Sci Adv. 7:eabj7398. PubMed
RRID
AB_2562051 (BioLegend Cat. No. 300537)
AB_314082 (BioLegend Cat. No. 300514)
AB_2564153 (BioLegend Cat. No. 300552)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Dendritic cells, Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC/Cyanine7 anti-human CD4 RPA-T4 FC
Brilliant Violet 785™ anti-human CD4 RPA-T4 FC
Brilliant Violet 605™ anti-human CD4 RPA-T4 FC
Brilliant Violet 711™ anti-human CD4 RPA-T4 FC
APC/Fire™ 750 anti-human CD4 RPA-T4 FC
CD4 Fluorophore Sampler Kit RPA-T4 FC
CD4 Fluorophore Sampler Kit with Veri-Cells™ PBMC RPA-T4 FC
TotalSeq™-A0072 anti-human CD4 RPA-T4 PG
TotalSeq™-B0072 anti-human CD4 RPA-T4 PG
TotalSeq™-C0072 anti-human CD4 RPA-T4 PG
Ultra-LEAF™ Purified anti-human CD4 RPA-T4 FC,CyTOF®,Activ,Block,IHC
APC anti-human CD4 RPA-T4 FC
Biotin anti-human CD4 RPA-T4 FC
FITC anti-human CD4 RPA-T4 FC,SB
PE anti-human CD4 RPA-T4 FC
PE/Cyanine5 anti-human CD4 RPA-T4 FC
PE/Cyanine7 anti-human CD4 RPA-T4 FC
Purified anti-human CD4 RPA-T4 FC,CyTOF®,Activ,Block,IHC
Alexa Fluor® 488 anti-human CD4 RPA-T4 FC,ICC
Alexa Fluor® 647 anti-human CD4 RPA-T4 FC,SB
Pacific Blue™ anti-human CD4 RPA-T4 FC
Brilliant Violet 421™ anti-human CD4 RPA-T4 FC,ICC
Alexa Fluor® 700 anti-human CD4 RPA-T4 FC,SB
PerCP anti-human CD4 RPA-T4 FC
PerCP/Cyanine5.5 anti-human CD4 RPA-T4 FC
Brilliant Violet 570™ anti-human CD4 RPA-T4 FC
Brilliant Violet 650™ anti-human CD4 RPA-T4 FC
Purified anti-human CD4 (Maxpar® Ready) RPA-T4 FC,CyTOF®
Alexa Fluor® 594 anti-human CD4 RPA-T4 FC,ICC
Brilliant Violet 510™ anti-human CD4 RPA-T4 FC
PE/Dazzle™ 594 anti-human CD4 RPA-T4 FC
TotalSeq™-D0072 anti-human CD4 RPA-T4 PG
APC/Fire™ 810 anti-human CD4 RPA-T4 FC
Spark UV™ 387 anti-human CD4 Antibody RPA-T4 FC
Go To Top Version: 3    Revision Date: 12-11-2023

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account